PsoProtect is an international registry developed to enable clinicians to report outcomes of COVID-19 in individuals with psoriasis. It is hoped that PsoProtect will help us to understand how immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis and it will provide real-time updates on cases reported for the benefit of the dermatology community. PsoProtect seeks to improve our understanding of how factors such as immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis.
IPC is pleased to be part of this important initiative and asks if you have a psoriasis patient diagnosed with COVID-19, please contribute to this important registry by submitting your case using the online PsoProtect case report form.
In addition, an adjoining registry PsoProtectMe has been set up for patients to self-report their experiences.
View the current data. You can also view our summary of the data collected from the first 50 cases, 200 cases, or 1002 cases.
WATCH NOW Catherine Smith, MD, and Savteer Mahil, MD, talk to IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD, about their goals for the PsoProtect patient registry to study COVID-19 and psoriasis.
Latest news Video Series on IPC’s Psoriasis Severity ReclassificationMarch 30, 2021Learn how psoriasis severity is currently measured and why a change is necessary, how IPC organized the Delphi process that was used to redefine severity classification, implications and effects the output has on psoriasis treatment providers and psoriasis patients, and ultimately how patients will benefit from this endeavor. Janssen Phase-3 TREMFYA® Clinical TrialMarch 29, 2021Janssen Pharmaceutical Companies of Johnson & Johnson published the long-term data of the third phase of the DISCOVER-2a study. Sun Pharma Phase-3 ILUMYA® Clinical TrialMarch 28, 2021Sun Pharmaceutical Industries Inc. announces results from their five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension. Update on PsoProtect Registry DataMarch 17, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1002 cases. More News
